• Something wrong with this record ?

Age is a critical determinant in recovery from multiple sclerosis relapses

BL. Conway, B. Zeydan, U. Uygunoğlu, M. Novotna, A. Siva, SJ. Pittock, EJ. Atkinson, M. Rodriguez, OH. Kantarci,

. 2019 ; 25 (13) : 1754-1763. [pub] 20181010

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20023549

OBJECTIVE: To evaluate the impact of age on recovery from multiple sclerosis relapses. BACKGROUND: Increasing disability in multiple sclerosis is a consequence of progressive disease and incomplete relapse recovery. METHODS: The first and last-ever relapse data (357 relapses in 193 patients) from the Olmsted County population-based multiple sclerosis cohort were systematically reviewed for age, fulminance, location (optic nerve, brainstem/cerebellar, spinal cord), peak deficit, and maximum recovery. Three different relapse-outcome measures were studied both as paired analyses and as an overall group effect: change from peak deficit to maximum recovery in raw functional system score related to the relapse (ΔFSS), a previously published FSS-based relapse-impact model, and change from peak deficit to maximum recovery in Extended Disability Status Scale (ΔEDSS) score. RESULTS: Older age was linearly associated with worse recovery in the ΔFSS outcome (p = 0.002), ΔEDSS outcome (p < 0.001), and the FSS-based relapse-impact model (p < 0.001). A multivariate analysis of ΔFSS outcome linked poor recovery to older age (p = 0.015), relapse location (transverse myelitis or brainstem/cerebellar syndrome; p < 0.001), and relapse fulminance (p = 0.004). CONCLUSION: Multiple sclerosis-relapse recovery declines in a linear fashion with increased age, which should be considered when making treatment decisions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023549
003      
CZ-PrNML
005      
20201214130349.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458518800815 $2 doi
035    __
$a (PubMed)30303037
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Conway, Brittani L $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA/ HealthPartners Neuroscience Center, Saint Paul, MN, USA.
245    10
$a Age is a critical determinant in recovery from multiple sclerosis relapses / $c BL. Conway, B. Zeydan, U. Uygunoğlu, M. Novotna, A. Siva, SJ. Pittock, EJ. Atkinson, M. Rodriguez, OH. Kantarci,
520    9_
$a OBJECTIVE: To evaluate the impact of age on recovery from multiple sclerosis relapses. BACKGROUND: Increasing disability in multiple sclerosis is a consequence of progressive disease and incomplete relapse recovery. METHODS: The first and last-ever relapse data (357 relapses in 193 patients) from the Olmsted County population-based multiple sclerosis cohort were systematically reviewed for age, fulminance, location (optic nerve, brainstem/cerebellar, spinal cord), peak deficit, and maximum recovery. Three different relapse-outcome measures were studied both as paired analyses and as an overall group effect: change from peak deficit to maximum recovery in raw functional system score related to the relapse (ΔFSS), a previously published FSS-based relapse-impact model, and change from peak deficit to maximum recovery in Extended Disability Status Scale (ΔEDSS) score. RESULTS: Older age was linearly associated with worse recovery in the ΔFSS outcome (p = 0.002), ΔEDSS outcome (p < 0.001), and the FSS-based relapse-impact model (p < 0.001). A multivariate analysis of ΔFSS outcome linked poor recovery to older age (p = 0.015), relapse location (transverse myelitis or brainstem/cerebellar syndrome; p < 0.001), and relapse fulminance (p = 0.004). CONCLUSION: Multiple sclerosis-relapse recovery declines in a linear fashion with increased age, which should be considered when making treatment decisions.
650    _2
$a dospělí $7 D000328
650    12
$a věkové faktory $7 D000367
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a relabující-remitující roztroušená skleróza $x patofyziologie $7 D020529
650    _2
$a obnova funkce $x fyziologie $7 D020127
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zeydan, Burcu $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA/ Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, USA.
700    1_
$a Uygunoğlu, Uğur $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA/ Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
700    1_
$a Novotna, Martina $u Department of Neurology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA/ Polyclinic Medicina Plus, Prague, Czech Republic.
700    1_
$a Siva, Aksel $u Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
700    1_
$a Pittock, Sean J $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.
700    1_
$a Atkinson, Elizabeth J $u Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
700    1_
$a Rodriguez, Moses $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.
700    1_
$a Kantarci, Orhun H $u Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 25, č. 13 (2019), s. 1754-1763
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30303037 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130348 $b ABA008
999    __
$a ok $b bmc $g 1595868 $s 1114225
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 13 $d 1754-1763 $e 20181010 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options